Literature DB >> 24777104

Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.

H Guet-Revillet1, A Emirian2, M Groh3, B Nebbad-Lechani4, E Weiss3, O Join-Lambert1, E Bille1, V Jullien5, J R Zahar6.   

Abstract

Cefoxitin could be an alternative to carbapenems in extended-spectrum-beta-lactamase-producing Escherichia coli (ESBL-EC) infections. However, pharmacological and clinical data regarding cefoxitin are limited. Using a recent pharmacological model and the MICs of ESBL-EC collected from pyelonephritis, we determined the probabilities to reach four pharmacological targets: free cefoxitin concentrations above the MIC during 50% and 100% of the administration interval (T>MIC = 50% and T>MIC = 100%, respectively) and free cefoxitin concentrations above 4× MIC during 50% and 100% of the administration interval (T>4MIC = 50% and T>4MIC = 100%, respectively). Cefoxitin could be used to treat ESBL-EC pyelonephritis, but administration modalities should be optimized according to MICs in order to reach pharmacological targets.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24777104      PMCID： PMC4135984          DOI： 10.1128/AAC.02509-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  [Cefoxitin and ESBL].

Authors:  M Boyer; A Bignon; R Dessein; K Faure; B Guery; E Kipnis
Journal:  Med Mal Infect       Date:  2012-02-16       Impact factor: 2.152

2.  Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations.

Authors:  E J Goldstein; D M Citron; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

4.  Alternatives to carbapenems in ESBL-producing Escherichia coli infections.

Authors:  D Fournier; C Chirouze; J Leroy; P Cholley; D Talon; P Plésiat; X Bertrand
Journal:  Med Mal Infect       Date:  2013-02-19       Impact factor: 2.152

5.  Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.

Authors:  Raphaël Lepeule; Etienne Ruppé; Patrick Le; Laurent Massias; Françoise Chau; Amandine Nucci; Agnès Lefort; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

6.  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Authors:  Arantxazu Isla; Iñaki F Trocóniz; Ignacio López de Tejada; Silvia Vázquez; Andrés Canut; Jesús Muriel López; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Eur J Clin Pharmacol       Date:  2012-01-15       Impact factor: 2.953

7.  Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli.

Authors:  S Ananthan; A Subha
Journal:  Indian J Med Microbiol       Date:  2005-01       Impact factor: 0.985

Review 8.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

9.  Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.

Authors:  Selvi Palasubramaniam; Sekaran Muniandy; Parasakthi Navaratnam
Journal:  J Microbiol Immunol Infect       Date:  2009-04       Impact factor: 4.399

Review 10.  Global spread of Carbapenemase-producing Enterobacteriaceae.

Authors:  Patrice Nordmann; Thierry Naas; Laurent Poirel
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883
View more
  14 in total

Review 1.  Antimicrobial resistance in hospital-acquired gram-negative bacterial infections.

Authors:  Borna Mehrad; Nina M Clark; George G Zhanel; Joseph P Lynch
Journal:  Chest       Date:  2015-05       Impact factor: 9.410

Review 2.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

3.  Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.

Authors:  O Senard; M Lafaurie; P Lesprit; Y Nguyen; X Lescure; A Therby; V Fihman; N Oubaya; R Lepeule
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-11       Impact factor: 3.267

4.  How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?

Authors:  Benoît Pilmis; Assaf Mizrahi; Céline Mory; Alban Le Monnier; Najoua El Helali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-27       Impact factor: 3.267

5.  Antimicrobial Resistance Patterns and Dynamics of Extended-Spectrum β-Lactamase-Producing Uropathogenic Escherichia coli in Cusco, Peru.

Authors:  Steev Loyola; Fátima Concha-Velasco; Jimena Pino-Dueñas; Nancy Vasquez-Luna; Paola Juarez; Carlos Llanos; Guillermo Salvatierra; Jesus Tamariz; Andres G Lescano
Journal:  Antibiotics (Basel)       Date:  2021-04-22

Review 6.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

7.  Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates.

Authors:  Olivia Senard; Frédérique Bouchand; Laurene Deconinck; Morgan Matt; Lesly Fellous; Martin Rottman; Christian Perronne; Aurélien Dinh; Benjamin Davido
Journal:  Ther Adv Infect Dis       Date:  2018-11-13

8.  Antimicrobial Susceptibility of Microorganisms Isolated from Patients with Intraabdominal Infection in Korea: a Multicenter Study.

Authors:  Young Kyung Yoon; Jieun Kim; Chisook Moon; Mi Suk Lee; Jian Hur; Hojin Lee; Shin Woo Kim
Journal:  J Korean Med Sci       Date:  2019-12-09       Impact factor: 2.153

9.  High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus.

Authors:  Leon Cantas; Kaya Suer; Emrah Guler; Turgut Imir
Journal:  Front Microbiol       Date:  2016-01-13       Impact factor: 5.640

10.  Occurrence of OXA-48 Carbapenemase and Other β-Lactamase Genes in ESBL-Producing Multidrug Resistant Escherichia coli from Dogs and Cats in the United States, 2009-2013.

Authors:  Xiaoqiang Liu; Kamoltip Thungrat; Dawn M Boothe
Journal:  Front Microbiol       Date:  2016-07-11       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.